Abstract-The Perceived Deficits Questionnaire (PDQ) is a part of the Multiple Sclerosis (MS) Quality of Life Inventory that assesses self-perceived cognitive difficulties. We used baseline data from 49 MS subjects participating in a clinical trial to evaluate the correlation of the PDQ with two measures of cognitive impairment, the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test, 2nd edition (CVLT-II), total score, and one measure of depression, the Beck Depression Inventory-Amended (BDI-IA). The PDQ correlated significantly (r = 0.42; 95% confidence interval [CI], 0.15 to 0.62; p = 0.003) with the BDI-IA scores but not with either the PASAT (r = -0.22; 95% CI, -0.48 to 0.06; p = 0.2) or the CVLT-II total (r = -0.17; 95% CI, -0.43 to 0.12; p = 0.25). A subset of 38 of these subjects who scored worse than 0.5 standard deviation below the mean on the PASAT or CVLT-II received a more extensive neuropsychological battery of tests. No significant correlations were found between any of these tests and the PDQ. These results suggest that self-perceived cognitive dysfunction relates more to depression than to objective cognitive dysfunction.
INTRODUCTION
Patients with multiple sclerosis (MS) can experience deterioration in their quality of life (QOL) in physical, cognitive, and emotional domains. Instruments that measure the impact of MS in health-related QOL have been developed to capture the impact of the disease on other domains besides physical disability. The prevalence of cognitive dysfunction in people with MS has been estimated to be between 45 and 65 percent [1] [2] . Cognitive impairment in people with MS is associated with decreased employment and social interactions [3] . Instruments for measuring QOL in MS should include useful scales that measure the impact of cognitive impairment. The MS QOL Inventory (MSQLI) is a modular MSspecific health-related QOL instrument consisting of a widely used generic measure, the 36-item short form Medical Outcomes Study Health Status Questionnaire that is supplemented by nine symptom-specific measures [4] . The Perceived Deficits Questionnaire (PDQ) is a part of the MSQLI and measures self-reported symptoms of psychological impairment. The MSQLI has been shown to have internal reliability and construct validity in a large sample of North American subjects [4] . To understand the contributions of objective impairment in standard neuropsychological tests and depression to self-perception of cognitive deficits, we used baseline data of 49 subjects to evaluate the correlation of the PDQ with the Beck Depression Inventory-Amended (BDI-IA) and with two neuropsychological tests, the Paced Auditory Serial Addition Test (PASAT) and the total score from the California Verbal Learning Test, 2nd edition (CVLT-II). We selected the PASAT and the CVLT-II total score because these two tests measure sustained attention and memory, respectively. These domains are frequently impaired in people with MS [1] [2] . The PASAT has also been routinely used in clinical trials in MS and is part of the MS Functional Composite. Both tests are easy to administer and have good population norms. In a subgroup of 38 subjects with below-average performance on the CVLT-II total score or the PASAT, we also determined the correlation of the PDQ with a more extensive battery of tests that included the Controlled Oral Word Association Test (COWAT), the Symbol Digit Modalities Test (SDMT), an adapted version of the useful field of view (UFOV), and the University of Victoria version of the Stroop color-word test (Stroop). We chose the SDMT and the Stroop as additional measures of attention and the COWAT as a measure of verbal fluency because performance on all three tests is frequently impaired in MS [1] . We chose the UFOV, although not extensively studied in MS, because it provides a measure of cognitive processing speed that is independent of a timed motor response. Research has shown that subjects with MS who are cognitively impaired perform worse on this test than healthy controls [5] [6] .
METHODS

Subjects
To conduct the analysis, we used baseline data from MS subjects who volunteered for a double-blind placebocontrolled trial of Ginkgo biloba for the treatment of cognitive impairment. The Oregon Health & Science University Institutional Review Board approved the study before initiation. All subjects who participated in the study signed an informed consent. For entry of participants into the parent Ginkgo biloba clinical trial, inclusion criteria were-1. Diagnosis of MS according to McDonald et al. criteria [7] .
2. Ages 18 to 60.
3. Subjective cognitive impairment.
English as primary language.
Exclusion criteria were-1. Score greater than 19 (moderate depression on the BDI-IA) [8] .
2. Requirement of a permanent caregiver.
3. Significant medical diseases such as insulin-dependent illnesses, uncontrolled hypertension, uncontrolled hypothyroidism, liver or kidney failure, significant lung disease, alcoholism or other drug abuse, a known bleeding diathesis, symptoms or signs of congestive heart failure, angina, or significant valvular disease.
4. Visual impairment worse than 20/50 (binocular).
5. Pregnancy.
6. Significant exacerbation in the prior 30 days.
Subjects who fulfilled the inclusion and exclusion criteria received the PASAT and CVLT-II. Subjects who scored worse than 0.5 standard deviation (SD) below the reported means for either test qualified for the treatment phase of the parent clinical trial, completed the PDQ, and underwent more detailed neuropsychological testing at the same visit [1, 9] . Subjects who scored better than 0.5 SD below the mean on both tests did not enter the parent clinical trial and received a PDQ in the mail that they completed and returned. The primary study analysis includes all subjects (49), and a subgroup analysis includes subjects (38) who participated in the parent Gingko biloba trial and received the more detailed neuropsychological battery.
Instruments
All subjects included in this report received the PASAT, CVLT-II, BDI-IA, and PDQ. Only those who scored worse than 0.5 SD below the mean on the PASAT or CVLT-II received the rest of the neuropsychological battery that included the COWAT [10] , SDMT [11] , an adapted version of the UFOV [12] , and the Stroop [13] .
The PASAT [11] is a frequently used cognitive test that measures working memory and sustained attention. Subjects are presented with a number every 3 seconds and instructed to add the latest number with the one immediately before. Approximately 25 percent of subjects with MS are impaired on this test [1] .
The CVLT-II is a test of memory and learning. Subjects listen to a list of 16 items belonging to four categories presented at one item a second and are then requested to repeat as many as they can remember. This procedure is repeated in five trials and the score for each trial is recorded. The total score (CVLT-II total) is the sum of the five trials. An interference trial with a different list of 16 items is then performed and the subjects are asked to recall this new list. This test is followed by subjects being asked to recall the items in the initial list (CVLT-II short delay free) and then again after they are provided with the categories as cues (CVLT-II short delay cued). After 20 minutes performing a distracter task, the subjects are asked to recall the initial items spontaneously (CVLT-II long delay free) and again after being provided with the categories as cues (CVLT-II long delay cued). In similar tests of learning and recent memory, 31 percent of subjects with MS are impaired [1] .
The BDI-IA is a self-report screening instrument for depression. It consists of 21 items that measure the severity of depression in adults [8] .
The PDQ consists of 20 items that address cognitive difficulties. Subjects rate their responses on a 5-point scale ranging from 1 (never) to 5 (almost always). The scale is made up of the following questions:
1 The COWAT is a measure of phonemic verbal fluency and consists of three word-naming trials [10] . The examiner asks subjects to say as many words as they can think of in 1 minute. Every word in the list is to begin with the same given letter. Each of the three trials uses a different letter for a total of three letters.
The SDMT assesses information processing speed and visual tracking [11] . Subjects are presented with rows of blank squares, each of which is associated with a symbol. Above these rows is a key that matches the symbols with given numbers. The task of the subject is to fill in the blank squares with the corresponding numbers using the key. The subjects give their answers verbally. The total number of correct responses in 90 seconds is the score.
The UFOV is a computer-based test of visual information processing, divided attention, and selective attention that quantifies the visual field area over which a patient can process rapidly presented visual information [12] . The test consists of a brief presentation of the stimulus image. The stimulus image is either a car or a van in the center of the screen and a car in one of eight possible peripheral locations. The subject is asked to determine whether the car or the van was presented and to identify in which of eight possible locations the peripheral car was located. The test measures cognitive processing speed independently of timed motor response. We modified the original version to determine a precise perceptual threshold. The testing determines the minimum stimulus duration necessary for the subject to respond correctly 75 percent of the time. In addition to the threshold determination, the number of errors made at durations above threshold is calculated. The number of errors above threshold divided by the number of trials results in the percentage error rate above threshold. This error rate reflects lapses in attention since the subject is known to be able to respond accurately at these stimuli durations.
The Stroop is a measure of concentration, attention, and mental flexibility [13] . The examiner shows subjects a card with a list of color names. Each color is printed in an ink of a color that does not match the name of the color; for example, "blue" is printed in green ink. The color names and the colors of the ink can be blue, green, yellow, or red. The order of the color names in the list and the color of the ink in which they are printed are random. The task is to name the color of each word, and the outcome is the time the subject takes to complete the list.
Statistical Analyses
We performed statistical analyses using proc CORR (correlation procedure) in SAS ® version 8.01 (SAS Institute Inc, Cary, North Carolina). We screened individual variables for normality using normal probability plots, histograms, and the Kolmogorov-Smirnov goodness-of-fit test. The PASAT showed moderate negative skewness that was corrected with a negative square root transformation. The Stroop and the UFOV also showed substantial positive skewness that was corrected with a log transformation. Scatter plots did not show significant deviations from assumptions of linear correlation analysis. Observations with extreme values or high influence in the diagnostics were checked for accuracy. Pearson's correlation coefficients (r) between the PDQ and BDI-IA and the PASAT and CVLT-II total score were computed for all 49 subjects. We also analyzed a subset of 38 of these subjects who scored worse than 0.5 SD below the mean on the PASAT or CVLT-II. Pearson's correlation coefficients between the PDQ, BDI-IA, COWAT, SDMT, UFOV, and Stroop were computed for this subset. We calculated confidence intervals (CIs) for the correlation coefficients using Fisher's transformation and normal approximation [14] . A p-value of 0.05 was considered significant for this part of the analysis.
As an exploratory analysis, correlations between the individual items of the CVLT-II and PASAT were computed. Bonferroni's correction for multiple comparisons was used for this part of the analysis, because the conservative criteria p-values <0.0008 were considered significant.
RESULTS
Study Profile
The study profile is presented in Figure 1 . Fifty-seven subjects fulfilled the inclusion and exclusion criteria and received the PASAT and CVLT-II. Of these subjects, 39 had scores on the CVLT-II or PASAT between 0.5 and 2.5 SD below the mean and qualified for the treatment phase of the clinical trial. These 39 subjects received the complete neuropsychological battery. Of these 39 subjects, 38 completed the PDQ form. Four subjects in this group did not complete one of the 20 questions in the PDQ. Two of them omitted question eight, one omitted question six, and one omitted question four. The missing values were replaced by the mean response for the whole sample. The analysis was repeated excluding these four subjects (not shown). Eighteen subjects did not have significant impairment in either the CVLT-II or PASAT. Of these subjects, 11 completed the PDQ. These 11 subjects answered all of the questions. Table 1 presents the demographics for the 49 subjects who completed the PDQ, BDI, PASAT, and CVLT-II total score. The sex distribution was similar to that expected from a population sample of MS subjects with more females than males. Table 2 shows the mean and SD scores for the PASAT, CVLT-II, BDI-IA, and PDQ for all subjects. Figure 2 shows the distribution of the z scores for the PASAT and CVLT-II total score on all subjects. The mean ± SD scores for the PASAT were similar to those seen in a large MS population study [1] . Of the subjects, 73 percent had no depression (BDI-IA score <9) and 27 percent had mild depression according to the BDI-IA (BDI-IA score 10-18). Table 3 shows mean ± SD score for the rest of the neuropsychological tests on the 38 subjects who received the complete neuropsychological battery, and Figure 3 shows the distribution of the z scores. The mean Expanded Disability Status Scale of this subset was 3.6 ± 1.4 SD.
Demographics
Correlations Between PASAT, CVLT-II, and BDI-IA with PDQ of All Subjects
The PASAT and the CVLT-II total score were significantly, though modestly, correlated (r = Table 4 shows the correlation matrix along with the respective p-values. Deleting the four subjects who were missing one item in the PDQ did not significantly alter the magnitude or the significance of the correlations between the PDQ and the BDI, PASAT, and CVLT-II total score.
Correlations Between Complete Battery Tests and BDI-IA with PDQ of Subgroup Subjects
Thirty-eight subjects had scores on the PASAT and CVLT-II total score worse than 0.5 SD below the mean and received the full neuropsychological battery. An analysis similar to the one performed on all the subjects did not show any significant correlations between the PDQ and any of the other neuropsychological tests. None of the additional tests in the battery correlated significantly with the BDI-IA. The correlation between the BDI-IA and PDQ persisted (r = 0.55; 95% CI, 0.32 to 0.72; p = 0.0004). The correlation matrix is presented in Table 5 .
Correlations Between Individual Items in PDQ and PASAT, CVLT-II Total Score, and BDI-IA
As an exploratory analysis, the correlations between the different specific items of the PDQ and the PASAT, CVLT-II total score, and BDI-IA were determined. Table 6 shows the correlations of the individual items of the PDQ with the CVLT-II total score and BDI-IA. Item 1, "Lose your train of thought when speaking?" (r = 0.51; 95% CI, 0.27 to 0.85; p = 0.0002), and item 3, "Forgot what you came into the room for?" (r = 0.48; 95% CI, 0.23 to 0.67; p = 0.0005), correlated highly with the BDI-IA. These correlations were significant after we adjusted for multiple comparisons. Item 14, "Forgot what you talked about after a telephone conversation?" and item 17, "Have trouble holding phone numbers in your head, even for a few seconds?" also showed a similar trend but did not reach the criteria for significance after we adjusted for multiple comparisons. None of the individual items had statistically significant correlations with the PASAT or the CVLT-II total score. However, item 2, "Have difficulty remembering the names of people, even the ones you have met several times?" (r = -0.31; 95% CI, -0.03 to -0.54; p = 0.03), item 15, "Forget to do things like turn off the stove or turn on your alarm clock?" (r = -0.32; 95% CI, -0.04 to -0.55; p = 0.03), and item 16, "Feel like your mind went totally blank?" (r = -0.33; 95% CI, -0.05 to -0.56; p = 0.2), showed modest correlations with the PASAT and not the BDI-IA, but these correlations did not reach the significance level after we adjusted for multiple comparisons. Item 18 , "Forget what you did last weekend?" also showed a similar trend for the CVLT-II total score (r = -0.30; Table 5 . Correlation coefficients (r) and p-values for PDQ and complete neuropsychological battery tests for subgroup (n = 38). 
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Stroop (s) - - - - - - - - r = 0.39 r = 0.18 r = 0.23 - - - - - - - - p = 0.02 p = 0.28 p = 0.16 UFOV - - - - - - - - - r = 0.22 r = 0.13 - - - - - - - - - p = 0.19 p = 0.43 BDI-IA - - - - - - - - - - r = 0.55 - - - - - - - - - - p =
DISCUSSION
This study suggests that the self-reported cognitive difficulties measured by the PDQ relate more to depression than to objective cognitive impairment, even in this sample that excluded subjects with moderate or severe depression. The PDQ did not significantly correlate with two objective neuropsychological tests that measure verbal memory (CVLT-II) and sustained attention (PASAT), two domains that are frequently impaired in MS. The results of the analysis of the subjects who received the extended battery further conclude that the PDQ does not correlate with objective measures of attention, information processing, or phonemic fluency. These results agree with previous studies in people with MS where no correlation was found between self-reported impairment measured with self-report instruments other than the PDQ and objective impairment in neuropsychological tests [15] [16] [17] . A study in people with MS did show significant correlations between self-report of memory on the Memory Rating Scale and delayed recall and attention tests, but this self-report instrument is oriented only to memory deficits [18] . Some self-report instruments may be better than others in correlating with objective measures of cognitive impairment. Studies in people with epilepsy [19] , schizophrenia [20] , and normal aging [21] have also failed to show a significant correlation between selfreport measures of cognitive impairment and objective testing. However, in longitudinal studies in aging and in human immunodeficiency virus, subjective cognitive deficits in initial testing were associated with developing cognitive difficulties on follow-up [22] [23] .
Some of the perceived deficits reported in the PDQ could possibly correlate with objective impairment in other domains that we did not test, such as executive function, visuospatial reasoning, or nonverbal memory. The tests we used measure the domains that are most Table 6 . Correlation coefficients (r) and p-values between individual items of PDQ and PASAT, CVLT-II total score, and BDI-IA for all subjects (n = 49).
frequently impaired in MS, so they would be expected to capture most of the cognitive impairment in the subjects. The content of most of the items in the PDQ suggests that they measure self-perceived deficits in working memory, verbal memory, and attention, so at least some of the items would be expected to correlate with the objective tests we used. This was not the case in the analysis of the individual items. Also possible is that the tests we used are not sensitive enough to capture slight impairment that subjects may still perceive. Further studies are needed to refine the PDQ as a measure of the impact of cognitive impairment on the QOL of MS patients by clarifying if some portions of it correlate with other objective tests not used in this study.
This study has other limitations. The sample size was small and the CIs do not exclude moderate correlation values, so moderate correlations were possibly missed due to chance and low power. Our study was also subject to selection bias because the subjects, the physician, or the family likely noted significant deficits that motivated the subjects to participate in the clinical trial; thus, it is possible that in a random sample of people with MS that includes subjects who are not symptomatic, the correlations between the PDQ and objective deficits would be higher.
We found that the PDQ had a moderately strong correlation with the BDI-IA. Similar results have been observed in other studies in MS using different selfreport instruments [15, 24] . Researchers should examine the correlation of the BDI-IA with the PDQ more closely in future studies to determine if it is driven by the two items in the BDI-IA that relate to difficulties in making decisions and working. Some of the items in the PDQ correlated very highly with depression, and since other scales in the MSQLI already address mood and affect, these items may not be needed. Larger studies could help further clarify which items could be deleted because of their high correlation with depression and which items correlate best with objective cognitive deficits.
The MS Neuropsychological Screening Questionnaire, a scale that is administered to a caregiver or close family member, correlated with objective performance, while a similar scale given to the subjects did not [15] . This finding suggests that observed and self-perceived cognitive impairment may be two different domains with the degree of impairment observed by an independent informant more closely related to what is measured by cognitive tests. Additional scales given to an informant may be necessary to capture the impact of cognitive impairment on QOL.
Since the PDQ did not correlate with any of the objective cognitive tests used in this study, what the PDQ actually assesses is uncertain. The BDI-IA score only accounted for a small portion of the variance in the PDQ scores. Obtaining norms from healthy populations and populations with other diseases could help clarify if the variance in the PDQ not accounted for by the BDI-IA is normal variability or a dimension of impairment specific for MS that is not captured by objective tests.
CONCLUSIONS
This study has two important clinical implications. First, the results from this study emphasize the importance of addressing depression in people with MS who have cognitive complaints. Even in individuals with low levels of depression, like the subjects in this study, depression had a significant association with self-perceived impairment, while objective results did not. Second, the results also emphasize that objective neuropsychological testing helps clarify the domains that are impaired and the severity of impairment in people with MS who have cognitive complaints. Clarifying the domains and the severity of impairment will help the clinician diagnose and provide the necessary treatment and counseling. Careful evaluation of cognitive impairment will become even more important in the future as therapies for cognitive impairment in MS become available.
